2025
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCN
2024
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Streiff M, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin K, Fogerty A, Crestani N, Gangaraju R, Rojas-Hernandez C, Goldhaber S, Ibrahim I, Kubal T, Leavitt A, Lim M, Mann J, Mantha S, Morton C, Nester A, O'Brien A, Ortel T, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 483-506. PMID: 39236759, DOI: 10.6004/jnccn.2024.0046.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesNCCN guidelinesClinical practice guidelinesVenous thromboembolismVenous thromboembolic diseaseNCCN panelCancer-associated venous thromboembolismInternal medicinePractice guidelinesMedical oncologyThromboembolic diseaseTreatment of venous thromboembolismNCCNLife-threatening conditionMultidisciplinary effortRecommended treatment optionGuidelinesOncologyAdult patientsTreatment optionsInterventional radiologyDiverse subtypesCancerPatientsPrevention
2019
Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis
Tan W, Trinh Q, Hayn M, Marchese M, Lipsitz S, Nabi J, Kilbridge K, Vale J, Khoubehi B, Kibel A, Sun M, Chang S, Sammon J. Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology Seminars And Original Investigations 2019, 38: 74.e13-74.e20. PMID: 31864937, DOI: 10.1016/j.urolonc.2019.11.008.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCT1a renal cell carcinomaImmediate nephrectomyKaplan-Meier curvesOverall survivalCell carcinomaSurgical resectionRenal massesPatient ageTreatment armsCharlson Comorbidity Index 0Compare OS of patientsLong-term overall survivalInfluence of patient ageCox proportional hazards regression analysisEarly surgical resectionLong-term OSMedian patient ageProportional hazards regression analysisMedian Follow-UpNational Cancer DatabaseOS of patientsSmall renal massesInverse probabilityRecommended treatment option
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply